Kiev, Ukraine (PRWEB) February 02, 2013
Ekomed company is pleased to announce that Immunoxel formulated into Honey Lozenges™ has been awarded Global Science & Technology Entrepreneurship Program (STEP) grant from the Civilian Research & Development Foundation (CRDF). CRDF is the non-profit organization authorized by the US Congress and established in 1995 by the National Science Foundation. STEP is funded by the US Department of State and in part by the State Agency of Ukraine for Science, Innovation, and Information. The grant will support clinical trial and joint marketing initiative of honey-formulated herbal supplement, Immunoxel, shown clinically effective as an immune adjunct against tuberculosis.
TB is a global killer. According to the WHO two billion people or 1/3 of the global population is latently infected with Mycobacterium tuberculosis. Annually, nearly 9 million of these people develop active TB and 2 million die. Current tuberculosis drugs are 50 years old, not very effective, must be taken for 6-9 months for drug-sensitive TB and up to 36 months for drug-resistant strains - MDR-TB and XDR-TB. Thus, new alternative approaches are urgently needed. One of them is immunotherapy, which is believed to enhance the efficacy of chemotherapy and shorten treatment duration.
The proprietary water-alcohol phytoconcentrate of 25 herbs, Immunoxel (Dzherelo), was developed by Ukrainian company Ekomed in 1997. This herbal tincture is widely available in Ukrainian pharmacies and has been used as an immune supplement to treat various infectious diseases such as seasonal flu, TB and HIV. Published studies spanning over the past 15 years count nearly tw
Copyright©2012 Vocus, Inc.
All rights reserved